ESTRO 2023 - Abstract Book

S977

Digital Posters

ESTRO 2023

CTCAE. Assessments were performed weekly from the start of treatment through to one-week following treatment completion.

Results 26 patients were allocated to receive SXRT, of whom 25 completed treatment using the product (Fig 1). The FEC control cohort consisted of 30 patients. Patient experience reported SXRT as easy to apply, with stickiness noted frequently and occasional discomfort. Correct application of SXRT (amount and area) was noted in 94% of interactions. Assessment completion rates were 98% and 41% for RTs and clinicians, respectively. No clear distinctions were demonstrated in toxicity between the groups, though aRISRAS trends suggested a reduced incidence of Gr3+ moist desquamation with SXRT compared to FEC (8% vs 23%, respectively) and faster recovery of skin reaction post-treatment with SXRT (Fig 2). Mean (range) utilisation of SXRT was 2.2 (1-4) 50g tubes per patient.

Conclusion This study confirms feasibility of SXRT in the management of radiation dermatitis for HNC patients. Further investigation is warranted to better define cost-benefit. RT involvement in standardised toxicity assessment enables high quality data to be consistently collected for the benchmarking of clinical outcomes.

PO-1221 "Quad-Shot" for incurable head and neck cancer improves OS when combined with systemic therapy

E. Nikolaidou 1,2 , D. Wollschlaeger 3,2 , H. Schmidberger 1,4

1 University Medical Center Mainz, Department of Radiation Oncology, Mainz, Germany; 2 German Cancer Consortium (DKTK) Partner Site Mainz, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3 Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center Mainz, Mainz, Germany; 4 German Cancer Consortium (DKTK) Partner Site Mainz, German Cancer Research Center (DKFZ), Hedeilberg, Germany Purpose or Objective The primary objective of this single institutional study was to estimate the efficacy and safety of hypofractionated palliative radiotherapy with or without concurrent systemic therapy of incurable primary, recurrent or metastatic head and neck cancer.